Renflexis® ,
Infliximab-abda
Disease
Crohn's disease
,
Ulcerative colitis
,
Drug Class
Biologics/Biosimilars
Delivery Method
IV
or
Brand name:
Renflexis®
(This drug is a biosimilar to Remicade©)
,Drug name:
Infliximab-abda
Drug type
Anti-TNF
Recommendations for pregnancy
low risk
Recommendations for breastfeeding
Limited human data: probably compatible
Most common side effects
Infusion reactions such as hives, redness, chest pressure, itching and swelling of the lips and throat and shortness of breath, respiratory infections, such as sinus infections and sore throat; headache; coughing; stomach pain; nausea; and back pain.
Other
There have been reports of serious infections associated with infliximab products, including tuberculosis (TB) and other infections such as viruses, fungi, and other bacteria that have spread throughout the body. On rare occasions certain types of cancer, including lymphoma, have been reported.
Learn more about
Biologics/Biosimilars